Acute hydrocortisone treatment increases anxiety but not fear in healthy volunteers: A fear-potentiated startle study

Biological Psychiatry

Volumn 69, Issue 6, 2011, Pages 549-555

  Grillon, Christian ^a   Heller, Randi ^a   Hirschhorn, Elizabeth ^a   Kling, Mitchel A ^b   Pine, Daniel S ^a   Schulkin, Jay ^c   Vythilingam, Meena ^d  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Office of the Assistant Secretary of Defense   (United States)

Author keywords

Amygdala; anxiety; BNST; corticotropin releasing hormone (CRH); cortisol; fear; predictability; startle reflex

Indexed keywords

HYDROCORTISONE; PLACEBO;

ADULT; ANXIETY; ARTICLE; AVERSION; CONTROLLED STUDY; DRUG EFFECT; FEAR; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SHOCK; STARTLE REFLEX;

ACOUSTIC STIMULATION; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS; ANXIETY; CONDITIONING, CLASSICAL; CROSS-OVER STUDIES; CUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROMYOGRAPHY; ELECTROSHOCK; FEAR; FEMALE; HUMANS; HYDROCORTISONE; MALE; RETROSPECTIVE STUDIES; SALIVA; STARTLE REACTION; TIME FACTORS; YOUNG ADULT;

EID: 79952042006     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2010.12.013     Document Type: Article

References (54)

1. Lupien SJ, Maheu F, Tu M, Fiocco A, Schramek TE (2007): The effects of stress and stress hormones on human cognition: Implications for the field of brain and cognition. Brain Cogn 65:209-237. (Pubitemid 350051538)
2. Shepard JD, Barron KW, Myers DA (2000): Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior. Brain Res 861:288-295. (Pubitemid 30173314)
3. File SE, Vellucci SV, Wendlandt S (1979): Corticosterone-An anxiogenic or an anxiolytic agent? J Pharm Pharmacol 31:300-305.
4. Cook CJ (2004): Stress induces CRF release in the paraventricular nucleus, and both CRF and GABA release in the amygdala. Physiol Behav 82:751-762.
5. Mitra R, SapolskyRM(2008): Acute corticosterone treatment is sufficient to induce anxiety and amygdaloid dendritic hypertrophy. Proc Natl Acad Sci U S A 105:5573-5578.
6. Thompson BL, Erickson K, Schulkin J, Rosen JB (2004): Corticosterone facilitates retention of contextually conditioned fear and increases CRH mRNA expression in the amygdala. Behav Brain Res 149:209-215. (Pubitemid 38199935)
7. Warburton DM (1974): Modern biochemical concepts of anxiety. Implications for psychopharmacological treatment. Int Pharmacopsych 9:189-205.
8. Putman P, Hermans EJ, Koppeschaar H, van Schijndel A, van Honk J (2007): A single administration of cortisol acutely reduces preconscious attention for fear in anxious young men. Psychoneuroendocrinology 32:793-802. (Pubitemid 47193170)
9. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, et al. (2006): Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A 103:5585-5590.
10. Perksy H, Smith KD, Basu GK (1971): Effect of corticosterone and hydrocortisone on some Indicators of Anxiety. J Clin Endocrinol Metab 33:467-473.
11. Makino S, Gold PW, Schulkin J (1994): Effects of corticosterone on CRH mRNA and content in the bed nucleus of the stria terminalis; comparison with the effects in the central nucleus of the amygdala and the paraventricular nucleus of the hypothalamus. Brain Res 657:141-149. (Pubitemid 24281258)
12. Swanson LW, Simmons DM (1989): Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: A hybridization histochemical study in the rat. J Comp Neurol 285:413-435. (Pubitemid 19184750)
13. Muller MB, Zimmermann S, Sillaber I, Hagemeyer T, Deussing JM, Timpl P, et al. (2003): Limbic corticotropin releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6:1100-1107. (Pubitemid 37186203)
14. Schulkin J, Morgan MA, Rosen JB (2005): A neuroendocrine mechanism for sustaining fear. Trends Neurosci 28:629-635. (Pubitemid 41654386)
15. Merali Z, Anisman H, James J, Kent P, Schulkin J (2008): Effects of corticosterone on corticotrophin-releasing hormone and gastrin-releasing peptide release in response to an aversive stimulus in two regions of the forebrain (central nucleus of the amygdala and prefrontal cortex). Eur J Neurosci 28:165-172.
16. Shepard JD, Chambers CO, Busch C, Mount A, Schulkin J (2009): Chronically elevated corticosterone in the dorsolateral bed nuclei of stria terminalis increases anxiety-like behavior. Behav Brain Res 203:146-149.
17. Davis M, Walker DL, Miles L, Grillon C (2010): Phasic vs sustained fear in rats and humans: Role of the extended amygdala in fear vs. anxiety. Neuropsychopharmacology 35:105-135.
18. Grillon C (2008): Models and mechanisms of anxiety: Evidence from startle studies. Psychopharmacologie 199:421-437.
19. Walker DL, Davis M (2002): Light-enhanced startle: Further pharmacological and behavioral characterization. Psychopharmacology(Berl) Berl 159:304-310. (Pubitemid 34143379)
20. Watts AG, Sanchez-Watts G (1995): Region-specific regulation of the neuropeptide mRNAs in rat limbic forebrain neurons by aldosterone and corticosterone. J Physiol 484:721-736.
21. Otto T, Poon P (2006): Dorsal hippocampal contributions to unimodal contextual conditioning. J Neurosci 26:6603-6609. (Pubitemid 44318341)
22. Grillon C, Baas JMP, Cornwell BR, Johnson L (2006): Context conditioning and behavioral avoidance in a virtual reality environment: Effect of predictability. Biol Psychiatry 60:752-759. (Pubitemid 44427771)
23. Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL (2007): Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biol Psychiatry 62:446-454. (Pubitemid 47284021)
24. Vansteenwegen D, Iberico C, Vervliet B, Marescau V, Hermans D (2008): Contextual fear induced by unpredictability in a human fear conditioning preparation is related to the chronic expectation of a threatening US. Biol Psychol 77:39-46. (Pubitemid 350309705)
25. Grillon C, Baas JP, Lissek S, Smith K, Milstein J (2004): Anxious responses to predictable and unpredictable aversive events. Behav Neurosci 118: 916-924. (Pubitemid 39346497)
26. Grillon C, Baas JP, Lissek S, Smith K, Milstein J (2004): Anxious responses to predictable and unpredictable aversive events. Behav Neurosci 118: 916-924. (Pubitemid 39346497)
27. Grillon C, Pine DS, Lissek S, Rabin S, Bonne O, Vythilingam M (2009): Increased anxiety during anticipation of unpredictable aversive stimuli in post-traumatic stress disorder but not in generalized anxiety disorder. Biol Psychiatry 66:47-53.
28. Grillon C, Lissek S, Rabin S, McDowell D, Dvir S, Pine DS (2008): Increased anxiety during anticipation of unpredictable but not predictable aversive stimuli as a psychophysiologic marker of panic disorder. Am J Psychiatry 165:898-904. (Pubitemid 351948722)
29. Grillon C, Chavis C, Covington MS, Pine DS (2009): Two-week treatment with citalopram reduces contextual anxiety but not cued fear. Neuropsychopharmacology 34:964-971.
30. Grillon C, Baas JMP, Pine DS, Lissek S, Lawley M, Ellis V, Levine J (2006): The benzodiazepine alprazolam dissociates contextual fear from cued fear in humans as assessed by fear-potentiated startle. Biol Psychiatry 60:760-766. (Pubitemid 44427760)
31. First MB, Spitzer RI, Williams JBW, Gibbon M (1995): Structured Clinical Interview for DSM-V (SCID). Washington, DC: American Psychiatric Press.
32. Spielberger CD (1983): Manual for the State-Trait Anxiety Inventory. Palo Alto, California: Consulting Psychologist Publishing Group.
33. Campeau S, Falls WA, Cullinan WE, Helmreich DL, Davis M, Watson SJ (1997): Elicitation and reduction of fear: Behavioural and neuroendocrine indices and brain induction of the immediate-early gene c-fos. Neuroscience 78:1087-1104. (Pubitemid 27223713)
34. Grillon C, Pine DS, Baas JMP, Ellis V, Charney DS (2006): Cortisol and DHEA-S are associated with startle potentiation during aversive conditioning in humans. Psychopharmacologie 186:434-441. (Pubitemid 43800844)
35. Cohen HH, Benjamin JJ, Kaplan ZZ, KotlerMM(2000): Administration of high-dose ketoconazole, an inhibitor of steroid synthesis, prevents posttraumatic anxiety in an animal model. Eur Neuropsychopharmacol 10:429-435.
36. Kellner M, Schick M, Yassouridis A, Struttmann T, Wiedemann K, Alm B (2004): Metyrapone tests in patients with panic disorder. Biol Psychiatry 56:898-900.
37. Belgorodsky A, Knyazhansky L, Loewenthal U, Arbelle J, Cohen H, Benjamin J (2005): Effects of the cortisol synthesis inhibitor metyrapone on the response to carbon dioxide challenge in panic disorder. Depress Anxiety 21:143-148. (Pubitemid 41040638)
38. Het S, Wolf OT (2007): Mood changes in response to psychosocial stress in healthy young women: Effects of pretreatment with cortisol. Behav Neurosci 121:11-20. (Pubitemid 46328621)
39. Reuter M (2002): Impact of cortisol on emotions under stress and nonstress conditions: A pharmacopsychological approach. Neuropsychobiology 46:41-48.
40. Buchanan TW, Brechtel A, Sollers JJ, Lovallo WR (2001): Exogenous cortisol exerts effects on the startle reflex independent of emotional modulation. Pharmacol Biochem Behav 68:203-210. (Pubitemid 32231181)
41. Monk C, Nelson C (2002): The effects of hydrocortisone on cognitive and neural function: A behavioral and event-related potential investigation. Neuropsychopharmacology 26:505-519. (Pubitemid 34261000)
42. Weiner S, Dorman D, Levitt E, Stach T, Persky H, Norton J (1963): Effect on anxiety of increasing plasma hydrocortisone level. Psychosom Med 25:69.
43. Levitt EE, Persky H, Brady JP, Fitzgerald JA (1963): The effect of hydorcotisone infusion on hypnotically induced anxiety. Psychosom Med 25: 158-161.
44. Persky H, Smith KD, Basu GK (1971): Effect of corticosterone and hydrocortisone on some Indicators of Anxiety. J Clin Endocrinol Metab 33:467-473.
45. Stark R, Wolf OT, Tabbert K, Kagerer S, Zimmermann M, Kirsch P, et al. (2006): Influence of the stress hormone cortisol on fear conditioning in humans: Evidence for sex differences in the response of the prefrontal cortex. Neuroimage 32:1290-1298. (Pubitemid 44278704)
46. Merz CJ, Tabbert K, Schweckendiek J, Klucken T, Vaitl D, Stark R, Wolf OT (2010): Investigating the impact of sex and cortisol on implicit fear conditioning with fMRI. Psychoneuroendocrinology 35:33-46.
47. Tabbert K, Merz CJ, Klucken T, Schweckendiek J, Vaitl D, Wolf OT, Stark R (2010): Cortisol enhances neural differentiation during fear acquisition and extinction in contingency aware young women. Neurobiol Learn Mem 94:392-401.
48. de Quervain DJ, Margraf J (2008): Glucocorticoids for the treatment of post-traumatic stress disorder and phobias: A novel therapeutic approach. Eur J Pharmacol 583:365-371.
49. Pugh CR, Tremblay D, Fleshner M, Rudy JW (1997): A selective role for corticosterone in contextual-fear conditioning. Behav Neurosci 111: 503-511. (Pubitemid 27251320)
50. Schmidt LA, Fox NA, Goldberg MC, Smidth CC, Schulkin J (1999): Effects of acute prednisone administration on memory, attention, and emotion in healthy human adults. Psychoneuroendocrinololy 24:461-483. (Pubitemid 29204806)
51. Grillon C, Levenson J, Pine DS (2007): A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: A fear-potentiated startle study. Neuropsychopharmacology 32:225-231. (Pubitemid 44967801)
52. Harmer CJ, Rogers RD, Tunbridge E, Cowen PJ, Goodwin GM (2003): Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacologie 167:411-417. (Pubitemid 36754243)
53. Kemp AH, Gray MA, Silberstein RB, Armstrong SM, Nathan PJ (2004): Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. Neuroimage 22:1084-1096. (Pubitemid 38829197)
54. Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A, et al. (2004): Low-dose cortisol for symptoms of posttraumatic stress disorder. Am J Psychiatry 161:1488-1490. (Pubitemid 38989105)